Adipotide (FTPP)：霊長類データと安全性の懸念を持つ脂肪血管標的ペプチド

For informational purposes only. This article does not constitute medical advice. Consult a qualified healthcare provider for any health-related decisions.

What Is Adipotide?

Adipotide, formally known as FTPP (fat-targeted proapoptotic peptide), is a chimeric peptide developed by Dr. Wadih Arap and Dr. Renata Pasqualini at the University of Texas MD Anderson Cancer Center. It represents a fundamentally different approach to fat reduction — rather than modulating metabolism, appetite, or fat cell biology, adipotide targets and destroys the blood vessels that supply white adipose tissue, causing fat cell death through vascular starvation.

The compound consists of two functional domains joined in a single peptide: a targeting motif (CKGGRAKDC) that selectively binds prohibitin on the surface of white adipose tissue (WAT) endothelial cells, and a proapoptotic motif (D(KLAKLAK)2) that disrupts mitochondrial membranes in the targeted cells, triggering apoptosis. This vascular-targeting strategy was originally developed in the context of cancer research (anti-angiogenic therapy) and was adapted for obesity applications based on the principle that adipose tissue, like tumors, is highly dependent on its blood supply. For context on other fat loss peptides, see our guide to fat loss peptides.

Mechanism of Action

Adipotide's mechanism involves a two-step process: selective vascular targeting followed by targeted cell destruction.

Step 1: Vascular Targeting via Prohibitin

• Prohibitin expression: Prohibitin is a protein expressed on the luminal surface of endothelial cells in white adipose tissue vasculature. While prohibitin is present in many cell types as an intracellular protein (primarily in mitochondria), its surface expression on WAT vasculature provides a selective targeting handle.
• Peptide homing: The CKGGRAKDC targeting motif was identified through in vivo phage display — a technique that screens random peptide libraries for sequences that home to specific vascular beds when injected into living animals. This sequence showed preferential accumulation in WAT vasculature.
• Tissue selectivity: The selectivity of adipotide for WAT vasculature over other vascular beds is the theoretical basis for its tissue-specific fat reduction. However, the degree of selectivity is imperfect, as prohibitin is expressed on vasculature of other tissues — a fact that contributes to off-target toxicity.

Step 2: Proapoptotic Cell Killing

• D(KLAKLAK)2 mechanism: After binding to prohibitin on the endothelial cell surface, adipotide is internalized. The D(KLAKLAK)2 domain is a synthetic peptide designed to disrupt mitochondrial membranes. It adopts an amphipathic alpha-helical structure that inserts into and permeabilizes the mitochondrial outer membrane, triggering cytochrome c release and caspase-mediated apoptosis.
• Endothelial cell death: Apoptosis of WAT endothelial cells leads to vascular collapse within the fat depot.
• Adipocyte ischemia: Without blood supply, adipocytes die through ischemic necrosis. The resulting fat tissue is gradually absorbed and cleared by macrophages and the immune system.

Research Findings

The Primate Study (2012)

The most significant adipotide study was published in Science Translational Medicine in 2012. In this study, obese rhesus macaques (a non-human primate model closely resembling human obesity) received daily subcutaneous injections of adipotide for 4 weeks. Key results included:

• Average body weight loss of 11% (range 7–15%)
• Average BMI reduction of 39%
• Significant reduction in abdominal fat (waist circumference)
• Improved insulin resistance (HOMA-IR index improvement)
• Fat loss was rapid, with effects visible within the first week of treatment

These results were dramatic — particularly the rapidity and magnitude of fat loss in a primate model without caloric restriction or increased exercise. The data generated enormous interest in the weight loss and research peptide communities.

Renal Toxicity

However, the same study revealed a serious safety concern: significant renal toxicity. All treated primates showed evidence of kidney damage, including:

• Elevated serum creatinine and blood urea nitrogen (BUN)
• Renal tubular necrosis on histological examination
• Proteinuria
• Reduced glomerular filtration rate

The renal toxicity was attributed to prohibitin expression on renal proximal tubular cells. As adipotide circulates through the renal vasculature, it encounters prohibitin-expressing cells in the kidney, leading to off-target killing of renal tubular cells. While the renal changes were partially reversible after treatment discontinuation, the severity was clinically significant and represented a major barrier to clinical translation.

Mouse Studies

Earlier mouse studies had demonstrated that adipotide selectively reduced white adipose tissue, improved metabolic parameters, and prevented diet-induced obesity. Interestingly, the renal toxicity observed in primates was less prominent in mouse studies, possibly reflecting species differences in prohibitin expression patterns or renal physiology — highlighting the importance of primate data for predicting human safety.

Safety and Tolerability

The safety profile of adipotide is its primary limitation. Beyond renal toxicity, additional concerns include:

• Non-selective vascular damage: Prohibitin is expressed on vasculature beyond WAT. Any off-target vascular ablation could cause ischemic damage to non-adipose tissues.
• Irreversibility: Unlike GLP-1 agonists or other metabolic treatments that can be discontinued with return to baseline, vascular ablation and fat cell death are largely irreversible processes. Excessive fat removal or damage to non-target tissues cannot be easily corrected.
• Inflammatory response: Large-scale fat necrosis generates a significant inflammatory burden as dead tissue is cleared, with potential systemic effects.
• Unknown long-term effects: The consequences of selectively removing WAT vasculature — which may also serve metabolic signaling, adipokine secretion, and immune functions — are not fully understood.

The risk-benefit assessment for adipotide is unfavorable given the availability of safer alternatives for weight management, including GLP-1 receptor agonists that achieve significant weight loss with manageable side effect profiles.

Regulatory Status

Adipotide is not FDA-approved and is not in active clinical development. Despite the impressive efficacy data in primates, the renal toxicity profile has prevented advancement to human clinical trials through standard regulatory pathways. The compound is available through some research peptide suppliers, but its use carries significant and well-documented safety risks. Individuals seeking weight management solutions should consult qualified healthcare providers about evidence-based, FDA-approved options with established safety profiles.